A federal judge in Minnesota refused to dismiss the core allegation that UnitedHealth Group manufactured $3.3 billion of earnings in 2024 to mask deterioration in its Medicare Advantage business, allowing the California Public Employees’ Retirement System to pursue its securities fraud case against the largest U.S. health insurer. The ruling narrows the battlefield considerably but leaves the most financially consequential claim intact.
The ruling in brief
U.S. District Judge Jeffrey Bryan granted UnitedHealth’s motion to dismiss on the majority of CalPERS’ allegations Wednesday, agreeing that most of the company statements cited by the pension fund amounted to non-actionable puffery or lacked the specificity required to support a fraud claim. The judge kept alive a single theory: that UnitedHealth concealed an illegal upcoding scheme that inflated risk scores for Medicare Advantage enrollees, thereby boosting government reimbursements and, by extension, reported earnings.
The allegation that survived
CalPERS contends the company used clinician home visits, marketed as preventive care, to add diagnoses to patient records without providing follow-up treatment, and pressured employed doctors through bonus structures to replicate the practice. The pension fund points to public statements describing those visits as keeping members healthy and clinical decisions as independent. Subsequent reporting has contradicted both characterizations. The $3.3 billion figure represents the earnings impact CalPERS attributes to the alleged concealment over the course of 2024.
What the judge threw out
Bryan found that UnitedHealth’s broader assurances about business strength, operational excellence, and compliance commitments were the kind of generalized optimism courts routinely treat as immaterial to investment decisions. The dismissal of those claims strips the complaint of its wider “scheme to inflate the stock” narrative and confines the litigation to the specific mechanics of risk-adjustment revenue.
What comes next
Discovery will now focus on internal communications, bonus formulas, and the clinical review processes governing home-visit diagnoses. UnitedHealth has denied wrongdoing and characterized the visits as legitimate care management. A trial date has not been set. The case remains a test of whether earnings derived from Medicare Advantage risk scores can be treated as fraudulent when the underlying coding practices face regulatory scrutiny.